Advanced Renal Cell Carcinoma (RCC)

Oncology·MeSH: Carcinoma, Renal Cell

Prevalence

48.0 / 100K

Incidence

15.0 / 100K/yr

5 drugs in development·4 companies·1 clinical trial

Drug Pipeline by Phase

Compare drugs

afinitor vs axitinibafinitor vs CABOMETYXafinitor vs Cabozantinib

Frequently asked questions

How many drugs are in development for Advanced Renal Cell Carcinoma (RCC)?

BioSniper tracks 5 drugs in development for Advanced Renal Cell Carcinoma (RCC) across 4 companies.

How many clinical trials target Advanced Renal Cell Carcinoma (RCC)?

There are 1 clinical trial targeting Advanced Renal Cell Carcinoma (RCC) tracked by BioSniper.

What is the prevalence of Advanced Renal Cell Carcinoma (RCC)?

The estimated prevalence of Advanced Renal Cell Carcinoma (RCC) is approximately 48.0 per 100,000 population.

Deep-dive into Advanced Renal Cell Carcinoma (RCC)

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Advanced Renal Cell Carcinoma (RCC) — Drugs in Development & Clinical Trials | BioSniper